Key result
Genotype-guided DAPT de-escalation saves ~€809,000 per 1,000 ACS patients while increasing QALYs over standard therapy.
Why the study?
Does a genotype-guided P2Y12-inhibitor de-escalation strategy improve cost-effectiveness compared to standard DAPT in patients with acute coronary syndrome?
Does a genotype-guided P2Y12-inhibitor de-escalation strategy improve cost-effectiveness compared to standard DAPT in patients with acute coronary syndrome?
A genotype-guided de-escalation strategy for P2Y12 inhibitors in ACS patients is cost-saving and yields higher QALYs compared to standard DAPT in the Dutch healthcare system.
Answers are grounded in this paper and cite their sources.
May support genotype-guided DAPT de-escalation in ACS; leaves open prospective validation before practice change.
AIMS: A genotype-guided P2Y12-inhibitor de-escalation strategy, switching acute coronary syndrome (ACS) patients without a CYP2C19 loss-of-function allele from ticagrelor or prasugrel to clopidogrel, has shown to reduce bleeding risk without affecting the effectivity of therapy by increasing ischaemic risk. We estimated the cost-effectiveness of this personalized approach compared to standard dual antiplatelet therapy (DAPT; aspirin plus ticagrelor/prasugrel) in the Netherlands. METHODS AND RESULTS: We developed a 1-year decision tree based on results of the FORCE-ACS registry, comparing a cohort of ACS patients who underwent genotyping with a cohort of ACS patients treated with standard DAPT. This was followed by a lifelong Markov model to compare lifetime costs and quality-adjusted life years (QALYs) for a fictional cohort of 1000 patients. The cost-effectiveness analysis was performed from the perspective of the Dutch healthcare system. A genotype-guided de-escalation strategy led to an increase of 57.73 QALYs and saved €808788 compared to standard DAPT based on a lifetime horizon. Probabilistic sensitivity analysis showed that the genotype-guided strategy was cost-saving in 96% and increased QALYs in 87% of simulations. The intervention remained cost-effective in the scenario where prices for all P2Y12 inhibitors were equalized. The genotype-guided strategy remained dominant in various other scenarios and sensitivity analyses. CONCLUSION: A genotype-guided de-escalation strategy in patients with ACS was both cost-saving and yielded higher QALYs compared to standard DAPT, highlighting its potential for implementation in clinical practice. Trial registration: ClinicalTrials.gov identifier: NCT03823547.
No takes yet. Share an insight, caveat, or question.
Broek et al. (2024) studied Acute coronary syndrome (n=1,000). Genotype-guided P2Y12-inhibitor de-escalation strategy vs. Standard dual antiplatelet therapy (DAPT; aspirin plus ticagrelor/prasugrel) was evaluated on Lifetime costs and quality-adjusted life years (QALYs) (Increase of 57.73 QALYs and saved €808788 per 1000 patients). A genotype-guided de-escalation strategy in ACS patients increased QALYs by 57.73 and saved €808,788 per 1000 patients over a lifetime horizon compared to standard DAPT.
Synapse has enriched 10 related papers. Consider them for comparative context: